GRTX vs. GHSI, AEZS, ERNA, ATHE, MTEM, BFRI, MBRX, GRAY, MNPR, and UPC
Should you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Guardion Health Sciences (GHSI), Aeterna Zentaris (AEZS), Eterna Therapeutics (ERNA), Alterity Therapeutics (ATHE), Molecular Templates (MTEM), Biofrontera (BFRI), Moleculin Biotech (MBRX), Graybug Vision (GRAY), Monopar Therapeutics (MNPR), and Universe Pharmaceuticals (UPC). These companies are all part of the "pharmaceutical preparations" industry.
Guardion Health Sciences (NASDAQ:GHSI) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, community ranking, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.
Guardion Health Sciences has higher revenue and earnings than Galera Therapeutics. Galera Therapeutics is trading at a lower price-to-earnings ratio than Guardion Health Sciences, indicating that it is currently the more affordable of the two stocks.
Guardion Health Sciences has a net margin of 0.51% compared to Guardion Health Sciences' net margin of 0.00%. Galera Therapeutics' return on equity of 2.01% beat Guardion Health Sciences' return on equity.
20.2% of Guardion Health Sciences shares are held by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are held by institutional investors. 1.3% of Guardion Health Sciences shares are held by insiders. Comparatively, 6.9% of Galera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Guardion Health Sciences has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.
Guardion Health Sciences received 12 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 67.39% of users gave Guardion Health Sciences an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote.
In the previous week, Guardion Health Sciences and Guardion Health Sciences both had 1 articles in the media. Galera Therapeutics' average media sentiment score of 1.87 equaled Guardion Health Sciences'average media sentiment score.
Summary
Guardion Health Sciences beats Galera Therapeutics on 10 of the 13 factors compared between the two stocks.
Get Galera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galera Therapeutics Competitors List
Related Companies and Tools
